https://www.selleckchem.com/products/ABT-888.html
70%) and control (168 patients; 50.30%). There were three outcomes that differed significantly between the two groups at 3 months mean difference of eGFR from baseline, proportion of patients with eGFR decline greater than 4 mL/min/1.73 m2, and difference in CKD stage from baseline. A significantly higher percentage of patients in the intervention group experienced CKD improvement by one stage (24.10% vs 5.95%), and a significantly lower percentage experienced decline by one stage (8.43% vs 35.12%) than in the control group. Conclusion
Gefällt mir
Kommentar
Teilen
